Caribou said it plans to use the capital toward developing its CRISPR-based platform, building its pipeline of oncology treatments, and growing its staff and operations. "This is an exciting moment for genome editing in the cell therapy space,” says CEO and Co-Founder Rachel Haurwitz, PhD . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge